The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | FIGHT update: 1L bemarituzumab in FGFR2b+ gastric cancer
Daniel Catenacci, MD, University of Chicago, Chicago, IL, presents an update on the FIGHT study (NCT03694522), a double-blind placebo-controlled Phase II study of bemarituzumab, an FGFR2b targeting antibody in combination with modified FOLFOX6 (mFOLFOX6) in the first-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. In this update, Dr Catencacci provides an updated analysis of patient subgroups, additional data on ocular adverse events and the median overall survival in the experimental arm. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Daniel Catenacci, MD has received support/funding from Genentech/Roche, Eli Lilly, Merck, Daiichi Sankyo, BMS, Ono, Five Prime, Seattle Genetics, Amgen, Taiho, Astellas, Gritstone, Pieris, Zymeworks, Basilea, QED, Arcus, Foundation Medicine, Tempus, Guardant Health, Archer, and Natera.
